The role for interleukin-12 therapy of cutaneous T cell lymphoma

Alain H. Rook; Mohamed H. Zaki; Maria Wysocka; Gary S. Wood; Madeleine Duvic; Louise C. Showe; Francine Foss; Michael Shapiro; Timothy M. Kuzel; Elise A. Olsen; Eric C. Vonderheid; Robert Laliberte; Matthew L. Sherman

doi:10.1111/j.1749-6632.2001.tb03721.x

The role for interleukin-12 therapy of cutaneous T cell lymphoma

Alain H. Rook, Mohamed H. Zaki, Maria Wysocka, Gary S. Wood, Madeleine Duvic, Louise C. Showe, Francine Foss, Michael Shapiro, Timothy M. Kuzel, Elise A. Olsen, Eric C. Vonderheid, Robert Laliberte, Matthew L. Sherman

Research output: Contribution to journal › Article › peer-review

52 Scopus citations

Abstract

Recent phase I and phase II trials using recombinant human interleukin-12 (rhIL-12) for cutaneous T cell lymphoma (CTCL) have been completed. Observations on 32 evaluable patients revealed an overall response rate approaching 50 percent. Biopsy of regressing lesions revealed an increase in numbers of CD8⁺ and/or TIA-1⁺ T cells. These results suggest that rhIL-12 may induce lesion regression by augmenting antitumor cytotoxic T cell responses. Future trials will be focused on strategies for further immune enhancement by the concomitant use of additional immune augmenting cytokines with rhIL-12.

Original language	English (US)
Pages (from-to)	177-184
Number of pages	8
Journal	Annals of the New York Academy of Sciences
Volume	941
DOIs	https://doi.org/10.1111/j.1749-6632.2001.tb03721.x
State	Published - 2001
Externally published	Yes

Keywords

Interferon-γ
Interleukin-2
Recombinant human interleukin-12

ASJC Scopus subject areas

General Neuroscience
General Biochemistry, Genetics and Molecular Biology
History and Philosophy of Science

Access to Document

10.1111/j.1749-6632.2001.tb03721.x

Cite this

@article{f47eb29a5fe34aed82a9829fd305ab11,

title = "The role for interleukin-12 therapy of cutaneous T cell lymphoma",

abstract = "Recent phase I and phase II trials using recombinant human interleukin-12 (rhIL-12) for cutaneous T cell lymphoma (CTCL) have been completed. Observations on 32 evaluable patients revealed an overall response rate approaching 50 percent. Biopsy of regressing lesions revealed an increase in numbers of CD8+ and/or TIA-1+ T cells. These results suggest that rhIL-12 may induce lesion regression by augmenting antitumor cytotoxic T cell responses. Future trials will be focused on strategies for further immune enhancement by the concomitant use of additional immune augmenting cytokines with rhIL-12.",

keywords = "Interferon-γ, Interleukin-2, Recombinant human interleukin-12",

author = "Rook, {Alain H.} and Zaki, {Mohamed H.} and Maria Wysocka and Wood, {Gary S.} and Madeleine Duvic and Showe, {Louise C.} and Francine Foss and Michael Shapiro and Kuzel, {Timothy M.} and Olsen, {Elise A.} and Vonderheid, {Eric C.} and Robert Laliberte and Sherman, {Matthew L.}",

year = "2001",

doi = "10.1111/j.1749-6632.2001.tb03721.x",

language = "English (US)",

volume = "941",

pages = "177--184",

journal = "Annals of the New York Academy of Sciences",

issn = "0077-8923",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - The role for interleukin-12 therapy of cutaneous T cell lymphoma

AU - Rook, Alain H.

AU - Zaki, Mohamed H.

AU - Wysocka, Maria

AU - Wood, Gary S.

AU - Duvic, Madeleine

AU - Showe, Louise C.

AU - Foss, Francine

AU - Shapiro, Michael

AU - Kuzel, Timothy M.

AU - Olsen, Elise A.

AU - Vonderheid, Eric C.

AU - Laliberte, Robert

AU - Sherman, Matthew L.

PY - 2001

Y1 - 2001

N2 - Recent phase I and phase II trials using recombinant human interleukin-12 (rhIL-12) for cutaneous T cell lymphoma (CTCL) have been completed. Observations on 32 evaluable patients revealed an overall response rate approaching 50 percent. Biopsy of regressing lesions revealed an increase in numbers of CD8+ and/or TIA-1+ T cells. These results suggest that rhIL-12 may induce lesion regression by augmenting antitumor cytotoxic T cell responses. Future trials will be focused on strategies for further immune enhancement by the concomitant use of additional immune augmenting cytokines with rhIL-12.

AB - Recent phase I and phase II trials using recombinant human interleukin-12 (rhIL-12) for cutaneous T cell lymphoma (CTCL) have been completed. Observations on 32 evaluable patients revealed an overall response rate approaching 50 percent. Biopsy of regressing lesions revealed an increase in numbers of CD8+ and/or TIA-1+ T cells. These results suggest that rhIL-12 may induce lesion regression by augmenting antitumor cytotoxic T cell responses. Future trials will be focused on strategies for further immune enhancement by the concomitant use of additional immune augmenting cytokines with rhIL-12.

KW - Interferon-γ

KW - Interleukin-2

KW - Recombinant human interleukin-12

UR - http://www.scopus.com/inward/record.url?scp=0034803597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034803597&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2001.tb03721.x

DO - 10.1111/j.1749-6632.2001.tb03721.x

M3 - Article

C2 - 11594571

AN - SCOPUS:0034803597

SN - 0077-8923

VL - 941

SP - 177

EP - 184

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

ER -

The role for interleukin-12 therapy of cutaneous T cell lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this